JPRN-UMIN000006058招募中2 期
Phase II trial of S-1 based therapy+/-Trastuzmab combination therapy for unresectable gastric cancer - S-1 based therapy+/-Trastuzmab combination therapy
2nd department of internal medicine Tottori University school of medicine0 个研究点目标入组 30 人开始时间: 2011年7月28日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •We exclude all patient who are not eligible for the inclusion
研究者
相似试验
已完成
2 期
Phase II trial of TS-1 plus Trastuzumab in patients with metastatic breast cancerbreast cancerJPRN-UMIN000004764Tokai University School of Medicine30
已完成
2 期
A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2 positive advanced gastric cancergastric cancerJPRN-UMIN000017602Cancer Institute Hospital Japanese Foundation For Cancer Research75
已完成
2 期
A Phase II Study of Trastuzumab plus S-1 in Patients with Advanced or Recurrent HER2 positive Breast CancerBreast cancerJPRN-UMIN000001408Gunma Breast Clinical Conference Study Group(GBCCSG)30
已完成
2 期
Phase II trial of Trastuzumab in combination with Abraxane for patients with HER2-positive metastatic breast cancerHER2-positive Metastatic breast cancerJPRN-UMIN000006159Kumamoto Breast Cancer Cooperative Group23
进行中（未招募）
1 期
Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxelon small cell lung cancer with a Her2 mutationMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10075653Term: HER2 gene amplificationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003506-11-FRIFCT45